Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07648043 · ClinicalTrials.gov registry record · Early Phase 1
Feasibilty and Acceptability of Amani
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
NCT07648043: Clinical Trial Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT07648043 is a Early Phase 1 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07648043, a Early Phase 1 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Adults with sickle cell disease (SCD) experience severe pain, emotional distress, and social isolation that diminish their quality of life. This project will test Amani, a novel virtual reality supportive care intervention designed to improve coping skills and strengthen peer support. If feasible and acceptable, Amani offers an accessible digital supportive care intervention to improve psychological well-being and quality of life among individuals living with SCD and potentially other chronic illnesses.
Interventions
- BEHAVIORAL Amani
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2027-01-01 |
| Est. Completion | 2028-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07648043
The ClinicalTrials.gov registry entry for NCT07648043 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amani is the first listed.
NCT07648043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07648043 about?
NCT07648043 is a clinical study titled "Feasibilty and Acceptability of Amani". Adults with sickle cell disease (SCD) experience severe pain, emotional distress, and social isolation that diminish their quality of life. This project will test Amani, a novel virtual reality supportive care intervention designed to improve coping skills and strengthen peer support. If feasible an...
What is the current status of trial NCT07648043?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2027-01-01. Estimated completion is 2028-04-30.
What interventions are being tested in trial NCT07648043?
The interventions under investigation include: Amani (BEHAVIORAL).
Who is sponsoring clinical trial NCT07648043?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.